Want to see HK:2616 full AI Analyst Report?
2616 Stock Chart & Stats
HK$5.34
HK$0.00(0.00%)
At close: 4:00 PM EST
HK$5.34
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$4.01 - HK$13.15
Previous CloseN/A
Volume1.16M
Average Volume (3M)19.75M
Market Cap
HK$7.43B
Enterprise ValueHK$5.88B
Total Cash (Recent Filing)HK$919.09M
Total Debt (Recent Filing)HK$348.67M
Price to Earnings (P/E)―
Beta1.22
Next Earnings
Aug 20, 2026EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding1,600,749,100
10 Day Avg. Volume13,736,900
30 Day Avg. Volume19,747,038
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)10.65
Price to Sales (P/S)24.38
P/FCF Ratio-20.05
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)HK$461.53M
Bulls Say, Bears Say
Bulls Say
2025 Revenue Rebound (+47.7% YoY)A 47.7% revenue rebound in 2025 signals improving commercial traction and patient uptake. If sustained, higher recurring sales can scale gross revenue, fund ongoing R&D and commercialization, and provide a firmer runway to address profitability and reduce reliance on external financing over the medium term.
Improved Leverage (debt-to-equity ~0.57)Debt-to-equity improving to ~0.57 from ~0.98 reflects a more moderate capital structure. Lower leverage reduces near-term refinancing pressure and gives the company greater flexibility to fund clinical programs, commercialization and partnerships while managing cash burn versus a more highly levered peer set.
Oncology / Immuno-oncology Focus With Commercialization Rights In ChinaA concentrated oncology and immuno-oncology portfolio plus commercialization rights in China anchors the company in a large, structural growth market. This model supports diversified revenue via direct product sales, licensing and royalties, and leverages local market access for durable commercial opportunities.
Bears Say
Sharp Margin Deterioration And VolatilityGross margin collapsing to ~17% and net margin widening to ~-162% indicate severe margin pressure and volatility. This undermines the quality of the revenue rebound since weak margins limit the firm’s ability to convert sales into sustainable profits and raise the execution bar for cost and pricing fixes.
Persistent Negative Operating And Free Cash FlowConsistent negative operating and free cash flow (-328M in 2025) means the company funds operations with external capital. Persistent cash burn raises financing and dilution risk, constrains ability to invest in commercialization or trials, and heightens vulnerability if funding markets tighten.
Deep Negative Returns And Ongoing Unprofitability (ROE ~-69%)ROE near -69% reflects deep capital erosion from sustained losses. Prolonged negative returns weaken equity base and limit strategic options, increasing the likelihood of further dilution or cutbacks in R&D/commercial programs absent a clear, durable path to profitability.
CStone Pharmaceuticals News
2616 FAQ
What was CStone Pharmaceuticals’s price range in the past 12 months?
CStone Pharmaceuticals lowest stock price was HK$4.01 and its highest was HK$13.15 in the past 12 months.
What is CStone Pharmaceuticals’s market cap?
CStone Pharmaceuticals’s market cap is HK$7.43B.
When is CStone Pharmaceuticals’s upcoming earnings report date?
CStone Pharmaceuticals’s upcoming earnings report date is Aug 20, 2026 which is in 50 days.
How were CStone Pharmaceuticals’s earnings last quarter?
CStone Pharmaceuticals released its earnings results on Mar 26, 2026. The company reported -HK$0.139 earnings per share for the quarter, missing the consensus estimate of -HK$0.058 by -HK$0.081.
Is CStone Pharmaceuticals overvalued?
According to Wall Street analysts CStone Pharmaceuticals’s price is currently Overvalued.
Does CStone Pharmaceuticals pay dividends?
CStone Pharmaceuticals does not currently pay dividends.
What is CStone Pharmaceuticals’s EPS estimate?
CStone Pharmaceuticals’s EPS estimate is -0.22.
How many shares outstanding does CStone Pharmaceuticals have?
CStone Pharmaceuticals has 1,600,749,100 shares outstanding.
What happened to CStone Pharmaceuticals’s price movement after its last earnings report?
CStone Pharmaceuticals reported an EPS of -HK$0.139 in its last earnings report, missing expectations of -HK$0.058. Following the earnings report the stock price went up 0.145%.
Which hedge fund is a major shareholder of CStone Pharmaceuticals?
Currently, no hedge funds are holding shares in HK:2616
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CStone Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
290.90%
12-Months-Change
Fundamentals
Return on Equity
-64.78%
Trailing 12-Months
Asset Growth
2.02%
Trailing 12-Months
Company Description
CStone Pharmaceuticals
CStone Pharmaceuticals is a biopharmaceutical company dedicated to the discovery, development, and commercialization of advanced immuno-oncology and precision medicines. Its mission is to address critical unmet medical needs for cancer patients, both within China and across the globe. The company's market-ready portfolio includes Sugemalimab, a monoclonal antibody targeting programmed death ligand 1 (PD-L1); GAVRETO, an RET inhibitor approved for advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers; and avapritinib, a KIT/PDGFRA inhibitor used to treat adults with unresectable or metastatic gastrointestinal stromal tumors featuring a PDGFRA exon 18 mutation. CStone also maintains a strong pipeline of investigational therapies, such as Nofazinlimab (a PD-1 antibody for hepatocellular carcinoma), Ivosidenib (an isocitrate dehydrogenase 1 (IDH1) inhibitor for adults with relapsed or refractory acute myeloid leukemia with an IDH1 mutation), and Fisogatinib (an FGFR4 inhibitor for hepatocellular carcinoma). Additional pipeline assets include CS1002, CS2006, CS3002, CS3005, CS2007, CS2008, and CS500, primarily for solid tumors, along with CS5001, intended for both solid and hematologic malignancies. Established in 2015, CStone Pharmaceuticals is headquartered in Shanghai, China.
Technical Analysis
Zai Lab Ltd
―
Alphamab Oncology
―
InnoCare Pharma Ltd.
―
CARsgen Therapeutics Holdings Ltd.
―
Ascentage Pharma Group International
―
Options Prices
Currently, No data available
---